Partner Content Partner Content On Demand: The Top 5 Challenges in Immuno-Oncology Trials In the battle against cancer, immunotherapy is proving to be one of the most promising avenues of research.
Views & Analysis Urgent need for clarity as government suspends pharmacy cut ... But reprieve may last only until plans have been reviewed.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.